The Enzyme Experts
0
0
Resources
Company
Contact
X

Essential insights based on 3rd party publications:

Get the White Paper now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

Quantification Challenges of Chromatin — Associated Host Cell DNA:
An Underestimated Risk

  • Discover why host cell DNA quantities are often significantly underestimated.
  • Understand the limitation of conventional nucleases when degrading chromatin

Download the poster here
and get access to the
interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

The Largest Overlooked Cost Driver in Viral Vector Production

  • Up to half of produced vector is lost during Down Stream Processing(DSP)
  • The majority of manufacturing cost accumulates is DSP raw materials
  • Nuclease design decisions determine downstream economics

Download here and get access to the interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Investors News

ArcticZymes Technologies has filed DMF for SAN HQ GMP

Jun 29, 2023

Tromsø, Norway, June 29th 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the filing of a Drug Master File (DMF) to the US Food and Drug Administration (FDA) for Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). ArcticZymes is pleased to announce the filing of a DMF (Type II) for SAN HQ GMP with the US FDA’s Center for

Read More
Read More
2023, Q1 results

Q1 2023 Results and presentation

May 3, 2023

Tromsø, Norway, 03rd May 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 6.1 million for the first quarter of 2023. Highlights from Q1 2023 ArcticZymes Technologies (AZT) had Q1 sales of NOK 31.2 million (Q1 2022: NOK 49.2 million, NOK 35.2 million adjusted for Covid effects in Q1 2022) AZT had

Read More
Read More
launches ArcticZymes Proteinase HQ

ArcticZymes Technologies launches ArcticZymes Proteinase HQ

Apr 18, 2023

Tromsø, Norway, April 18nd 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the launch of ArcticZymes Proteinase HQ to the B2B market. Following up on earlier press-releases (9th Dec 2022) ArcticZymes is pleased to launch the latest member in our Proteinase product portfolio: ArcticZymes Proteinase HQ. This product is the ‘bioprocessing grade’ version of our existing successful ArcticZymes Proteinase and will be

Read More
Read More

ArcticZymes Technologies announces CEO resignation

Mar 22, 2023

Tromso, March 22nd 2023 – ArcticZymes Technologies ASA (OSE: AZT) announces that the Board of Directors has today accepted the voluntary resignation of Jethro Holter as Chief Executive Officer, due to personal reasons. The resignation will take effect on 30th September 2023 after the required 6 months notice period. “On behalf of the Board, I want to thank Jethro very

Read More
Read More